AgingResearch.NewsJoin free

MRNA-1273

Intervention

4 papers3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 3 independent labs in 1 country
  • 1 finding against
  • Funders: National Heart, Lung, and Blood Institute and 5 more
  • 1 of 3 findings with company ties
  • Humans4

Outcomes

2

Antibody avidity

upin humans1downin humans1

2 studies

  1. MRNA-1273 increases antibody avidity in humans (p < 0.001).

    “Notably, avidity increased to peak levels after the booster (p < 0.001).”

    Human trial6 monthsn = 15

    Frailty impacts immune responses to Moderna COVID-19 mRNA vaccine in older adults

    Immunity & ageing : I & AJan 17, 2023

  2. MRNA-1273 decreases antibody avidity in humans.

    “Antibody avidity significantly declined following 2 vaccine doses regardless of frailty status”

    Human trialfollowing 2 vaccine dosesn = 15

    Frailty and Age Impact Immune Responses to Moderna COVID-19 mRNA Vaccine

    Research squareAug 1, 2022Preprint

More on Antibody avidity

PCHorvath

downin humans1

1 study

  1. MRNA-1273 decreases PCHorvath in humans (-3.91 years).

    “vaccination significantly reduced principal component-based Horvath epigenetic clock estimates in people over 50 by an average of 3.91 years for those who received Moderna.”

    Human trialModernabloodn = 36

    Longitudinal Study of DNA Methylation and Epigenetic Clocks Prior to and Following Test-Confirmed COVID-19 and mRNA Vaccination

    Frontiers in geneticsJun 3, 2022

More on PCHorvath

Latest

Related